Dry Eye Disease MoA Animation
Novartis’ product, Xiidra®, is a non-steroid therapy that can disrupt inflammation and has been designed to target the underlying inflammation which is believed to fuel dry eye disease (DED).
This Mechanism of Action (MoA) animation was produced to inform the audience about the causes of dry eye disease and how the product could help treat the signs and symptoms of this. With clear branding guidelines set, this project aimed to exceed the client’s expectations by creating an immersive and captivating experience.
This animation has won 18 global industry awards.
This animation has featured online as part of the Xiidra® website. The animation has also been included in a virtual booth that explores some of Novartis’ ophthalmology products as part of the 2020 American Academy of Ophthalmology Annual Meeting.
Are you interested in seeing how our award-winning medical animation can help you?
Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.
‘‘For experts, there’s limited time in which they will interact with this content, so getting a message across quickly is crucial, and this medium does it very well.’’
Product Manager, GSK
‘‘Their turnaround time sets them apart from the rest of the field. The fact they can turnaround lots of comments in a couple of days is impressive, whereas that took weeks with other agencies we worked with. They’re well above the benchmark.’’
Oncology Clinical Liaison, Bristol-Myers Squibb
‘‘It was a combination equally of quality of work but also the comfort and confidence that I knew I would be working with PhDs. They gave me the confidence that they would have the ability to understand. The other companies didn’t have those sorts of people on staff, they were just good animators. That was the area where I felt that I could trust Random42 would deliver.’’
Senior Product Manager, Spectranetics
‘‘I have been to a lot of conferences and I have seen a lot of videos both from competitors and internally – in my eyes it is night and day. The quality Random42 have is not one step ahead, it is far ahead compared to what I have seen before.’’
Product Manager, Amgen